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 ABSTRACT 
 
 
 
 
LIM Kinase 1 (LIMK1), a serine/threonine kinase, modulates actin polymerization and 
microtubule assembly. The function of LIMK1 is regulated by kinases that are activated by 
Rho and Rac GTPases.  LIMK1 is overexpressed in various cancerous cell types and tissues 
and its overexpression promotes increased invasion and metastasis of breast and prostate 
cancer cells. Membrane-Type Matrix Metalloproteinase 1 (MT1-MMP) is a member of the 
zinc-binding collagenase family, which is involved in extracellular matrix breakdown and 
activation of secreted MMP-2.   The balance between activation and inhibition of MT1-
MMP and MMP-2 helps maintaining normal extracellular matrix turnover. However, it has 
been shown that elevated MT1-MMP expression can cause excessive ECM digestion and 
promote tumor invasion and metastasis. Since RhoA and Rac1 have been implicated in 
metastasis and invasion along with LIMK1 activation, we investigated a possible link 
between LIMK1 and MT1-MMP. Our results show that the level of MT1-MMP expression is 
correlated with that of LIMK1 and LIMK1 acts as a transcriptional regulator of MT1-MMP.  
Additionally, we show that LIMK1 physically associates with MT1-MMP and promotes its 
translocation to the plasma membrane.
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1. INTRODUCTION 
 
 1.1 LIM Kinase 1 
 
 
LIM Kinase 1 (LIMK1) is a dual specificity serine/threonine and tyrosine kinase 
involved in modulating actin and microtubule dynamics.   It is a member of the small 
family of LIM domain containing kinases, which also includes LIM Kinase 2.  LIMK1 contains 
two LIM domains in tandem at the N-terminus, a PDZ domain, and a kinase domain at the C-
terminus (Figure 1) [Okano et al., 1995]. LIM domains are zinc -coordinating loops, which are 
involved in protein- protein interactions.  The residues involved in zinc interactions are 
highly conserved while the residues in the center of the loop are more variable and provide 
the diversity for specific interactions with different proteins. In addition to the LIM domains, 
the PDZ domain is also believed to be involved in mediating protein-protein interactions. 
LIMK1 also contains a nuclear localization sequence in its kinase domain along with two 
nuclear exit signals in the PDZ domain [Yang and Mizuno, 1999]. 
Inactive LIMK1 exists in a closed conformation state, which is a result of its LIM 
domains associating with its C-terminal kinase domain. Activating phosphorylation at Thr508, 
located within the kinase domain, induces a conformational change that allows its kinase 
domain to be able to interact with its substrates (Figure 2) [Edwards et al., 1999]. The activity 
of LIMK1 is also modulated through association with Hsp90 leading to transphosphorylation 
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and an increased half-life (Figure 2) [Li et al., 2006]. LIMK1 is phosphorylated by kinases that 
are activated by the Rho subfamily of small GTPases [Lou et al., 2001]. 
Two members of the Rho family, Rac1 and Cdc42 mediate activation of LIMK1. Rac1 
and Cdc42 in their GTP bound form bind to an inactive PAK1/4 homodimer. This binding 
causes the inhibitory domain of one PAK protein to disassociate from the kinase domain of 
the other PAK protein [Stofega et al., 2004]. Activated PAK1/4 can then phosphorylate LIMK1, 
which promotes formation of lamellipodia and filopodia. In addition to Rac1 and Cdc42, 
GTP-bound RhoA also activates LIMK1 through recruitment and activation of Rho kinase   
ROCK. Activated ROCK phosphorylates LIMK1 at T508 and activates it [Lin et al., 2003].  The 
RhoA signaling pathway induced activation of LIMK1 leads to the formation of actin stress 
fibers.Activation of LIMK1 is involved in stabilizing the actin cytoskeleton through the 
inactivating phosphorylation  of  Cofilin  at  Ser3   [Arber  et  al.,  1998].    This 
phosphorylation prevents Cofilin from severing actin filaments to globular (G) actin and 
results in the accumulation of filamentous (F) actin (Figure 2), [Moriyama et al., 1996]. 
Slingshot Phosphatase functions in opposition to this action by removing the phosphate 
group on Cofilin, restoring its activity and causing the increase in G-actin. In addition to 
stabilizing actin filaments, LIMK1 can cause a reduction of microtubule stability through its 
association with Tubulin-Polymerization Promoting Protein alpha (TPPP-α). The inhibitory 
phosphorylation of TPPP-α on serine residues by LIMK1 promotes the disassembly of tubulin 
polymers [Acevedo et al., 2007]. 
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  Figure 1: Structure of LIM Kinase 1 
 
LIM Kinase 1 contains two N-terminal LIM domains, a PDZ domain, and a C-terminal Kinase 
domain.   A nuclear localization signal is located in the Kinase domain and two nuclear 
exit signals are located in the PDZ domain. 
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(Tapia T., 2007) 
 
                                                  Figure 2: Activation and Function of LIM Kinase 1 
 
A) GTP bound Cdc42 and Rac1 bind to PAK1 homodimers resulting 
in dissociation and transphosphorylation of PAK1. Active PAK1 
phosphorylates LIMK1 at T508, causing a conformational change 
that activates LIMK1 and allows binding of Hsp90 leading to trans- 
phosphorylation and increased stability. B) Phosphorylation of 
cofilin at Ser3 by LIMK1 inactivates cofilin. As a result cofilin is 
unable to bind to and induce severing of filamentous actin. C) 
Dephosphorylation of cofilin by slingshot restores its activity. 
Resulting in the disassociation of actin subunits. 
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1.2 Role of LIM Kinase 1 in Cancer Progression 
 
 
The  progression  of  cancer  to  a  metastatic  state  is  associated  with  loss  of  
contact inhibited growth, increased cell mobility, and acquiring the ability to evade the 
primary tumor site and invade secondary organs.   Increased activity of Rho GTPases is 
noted in a variety of cancers,   which   results   in   deregulation   of   pathways   involved   in   
modulation   of   actin cytoskeleton.  Loss of regulation can lead to cell polarization and 
induce structures associated with cell mobility and invasion. These processes rely on 
stabilized actin filaments to provide the necessary forces need to drive changes in cell 
morphology.   The actin depolymerizing family includes the protein cofilin, which is a 
known substrate of LIMK1.   Inactivation of cofilin by LIMK1 results in local stabilization of 
actin filaments.   LIMK1 and cofilin localize to focal adhesions and to the membrane ruffles of 
lamellipodia at the plasma membrane. Overexpression of LIMK1 is associated with an 
invasive cancer and was shown to promote formation of invadopodia.  Although actin 
cytoskeleton reorganization is a key step in invasion, degradation of extracellular matrix is 
an important initial event that allows tumor cells to escape the primary site, which leads 
to distant metastasis. One group of proteolytic proteins integral   in   these   events   is   the   
family   members of   Matrix   Metalloproteinase (MMP). Additionally, increased activity of 
Rho signaling cascades are associated with enhanced expression, activation, and localization 
of MMPs. 
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1.3 Matrix Metalloproteinases 
 
 
Matrix metalloproteinases (MMP) are zinc-binding endopeptidases involved in 
maintaining the dynamic balance of the extracellular environment through regulated 
degradation of the ECM and basement membrane [Kessenbrock et al., 2010].  These 
enzymes play diverse roles in tissue remodeling, organ development, inflammation, and 
cancer. Twenty three MMP family members that are expressed in humans share common 
characteristics including structural elements, Zn dependence, and tight regulation.   These 
shared structural features include the N-terminal signal peptide, propeptide, catalytic 
domain, and a C-terminal hemopexin-like domain connected by a flexible hinge region 
[Visse, Nagase, 2003].  The MMP family is sub-classified into two groups: soluble or 
membrane associated members.  Membrane associated MMPs, in which MT1-MMP is 
classified, have a transmembrane domain ending in a short cytoplasmic tail or instead linked 
to a GPI anchor (Figure 3).     MMP regulation begins at the transcriptional level and requires 
the activation of transcription factors, including Sp1 and AP-1, to initiate transcription of the 
pro-enzymes [Sroka et al., 2007][Benbow et al., 1996]. Like many other proteolytic enzymes, 
MMPs are expressed as a zymogen providing additional control over activity. Latent MMP 
molecules have the cysteine residue, present in the prodomain,  associated  with  the  zinc  
ion  present  at  the  catalytic  site.    This conformation prevents the catalytic domain from 
interacting and cleaving its substrates. The cysteine switch mechanism is the next regulatory 
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step that requires the cleavage or modification of the prodomain to activate the MMP [Van 
Wart et al., 1990].   Cleavage events for secreted and membrane associated MMPs occur 
at different locations.    Both types have their signal sequence cleaved upon entry or 
integration into the ER, and are transported through the Golgi to specific areas of the 
membrane.   Soluble MMPs can then be secreted into the extracellular environment where 
processing to the active form occurs.  Alternatively, membrane-associated MMPs are 
activated by a convertase during transport and then are tethered to or integrated into the 
plasma membrane.  Further regulation of MMP activity is modulated by expression of Tissue 
Inhibitors of Metalloproteinases (TIMPs). TIMPs bind MMPs and block their active site 
inhibiting their catalytic activity, although TIMP2 has an additional role in the activation 
of MMP-2. 
MMPs participate in normal physiological processes including roles in tissue 
remodeling and angiogenesis.   Under normal physiological conditions, MMP activity is 
tightly controlled at multiple levels but loss of this regulation can lead to excessive 
degradation of the ECM and events associate with cancer progression.   MMPs have long 
been linked with cancer and invasion.   Early research sought inhibitors to reduce the activity 
of these peptidases; unfortunately the inhibitors were not effective in significantly changing 
the disease outcome in patients. This may be partially explained by more recent research 
showing additional role of MMPs in cancerous tissue beyond degrading basement 
membranes. MMPs participate in the complex cross talk between the cancerous tissue and 
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stromal cell and alter intracellular signaling. These findings suggest MMPs can modify 
tumor vasculature, inhibit apoptosis, and promote cell proliferation. Additionally, MMPs can 
induce epithelial-to-mesenchymal transition (EMT), a hallmark of advanced stage cancers. 
One important member of the MMP family is MT1-MMP, also known as MMP-14. 
MT1- MMP is anchored to the membrane by its transmembrane domain and positioned with 
the catalytic domain in the pericellular space.  MT1-MMP has roles in normal development 
along with cancer progression. It is found to be overexpressed in a variety of tumor tissues 
(Visse et al., 2003). Functions of MT1-MMP include degradation of multiple ECM 
components, activation of MMP-2, promotion of cell migration, and regulation of growth 
in 3-D tissue environment. With many diverse functions, cells have evolved a complex 
means of regulation for MT1-MMP. Starting at the transcriptional level, activation of the 
transcription factor Sp1 drives expression of proMT1-MMP. Next, the propeptide is cleaved 
in the Golgi by furin convertase producing the active enzyme [Yana et al., 2000] that is 
targeted to the plasma membrane. This cleavage along with glycosylation, are speculated to 
modulate localization and substrate specificity of MT1- MMP [Wu et al., 2007][Wu et al., 
2004]. The activity of membrane-integrated MT1-MMP undergoes  further  regulation  by  
the  levels  of  expressed  TIMP2  [Strongin  et  al.,  1995]. Additional regulatory processes 
include inactivation by autocatalytic shedding, and endocytosis [Osenkowski et al., 2004]. 
One of the major functions of MT1-MMP is the proteolytic activation of secreted 
proMMP-2. Elevated expressions of MT1-MMP, MMP-2, and MMP-9 are positively 
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correlated with  tumor  progression,  invasiveness,  and  poor  patient  survival  [Deryugina  
et  al.,  2006]. Activation of proMMP-2 by MT1-MMP requires sub saturation expression 
levels of TIMP2. TIMP2 binds and inhibits MT1-MMP but is still free to bind the hemopexin-
like domain of proMMP-2.   The resulting MT1-MMP/TIMP2/proMMP-2 complex can now 
associate with a neighboring TIMP2-free MT1-MMP molecule through the hemopexin 
domains of both MT1- MMP molecules, initiating cleavage of proMMP-2 (Figure 4), [Itoh et 
al., 2001]. Furthermore, MT1-MMP/TIMP2/MMP-2 complexes can cleave and activate 
secreted proMMP-9, in a TIMP-2 dependent activation cascade starting with MT1-MMP [Toth 
et al., 2003]. 
 
 
 1.4 Role of MT1-MMP in Cancer Progression 
 
 
MT1-MMP has many functions in the development of metastatic cancers, and its 
expression is associated with increased invasiveness of cancerous cells. Invasion begins at 
the invadopodia, similar to lamellipodia, which are specialized membrane protrusions 
containing actin scaffolding that penetrate the substrate below. This penetration requires 
the degradation of the extracellular matrix by secreted and membrane associated proteases.   
An essential mediator of this process, MT1-MMP is localized to these regions, and also 
promotes MMP-2 localization through binding to its hemopexin domain [Kim et al. 1998].  
MT1-MMP can then degrade multiple ECM substrates including collagens, laminins, and 
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fibronectin. This physically allows the cells to migrate but also reveals cryptic binding sites 
on the cell surface that play additional roles.  The cleavage of laminin-5 by MT1-MMP 
promotes increased cell motility and this effect is amplified by MMP-2, which is activated by 
MT1-MMP [Koshikawa et al., 2000].  In addition to cancer cell motility, cleavage of collagen-
IV reveals a cryptic binding site, which promotes migration of vascular endothelial cells.   The 
invasion and migration of vascular endothelial cells is a critical event required for 
angiogenesis.   Additionally, MT1-MMP can degrade the fibrin matrix surrounding new 
vessels [Hiraoka et al., 1998]. This potentially allows for increased sprouting of new vessels 
and increased circulation to the tumor. During the development of new vasculature, newly 
formed vessels are leaky and have loose cellular junctions especially in the lymphatic vessels.  
This increases the ability of cancerous cells to become metastatic by escaping the tumor and 
entering circulation. Circulating tumor cells then need to escape the blood vessels and enter 
surrounding tissues.   This process is called extravasation and expression of MT1-MMP is 
involved in these events {Tsunenzuka et al., 1996].   Extensive research has been 
conducted on regulation of expression and functions of MT1-MMP, some of which has 
been described, but still many aspects remain to be elucidated. This can partially be 
explained by the diverse roles of MT1-MMP and the impact other MMPs have on cell-cell 
cross talk.   Although broad-spectrum inhibitors of MMP initially looked promising because 
of the structural similarities among MMPs, non- oncogenic MMPs are also inhibited by 
these inhibitors. As a result, significant side effects, high toxicity and limited effectiveness of 
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these inhibitors made them failed clinically.  New therapeutics needs to be developed with 
reduced toxicity, which may be achieved through the inhibition of multiple oncogenic 
proteins through combination therapy or inhibiting specific MMP, such as MT1- MMP. 
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    Figure 3: Structural Organization of proMT1-MMP and proMMP-2 
 
Common structural elements shared by MMPs include the signal peptide, propeptide 
 
(containing Cys residue), and Zn binding catalytic domains. 
pro-MT1-MMP pro-MMP-2 
Signal Peptide 
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Cleavage Site 
Catalytic 
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Transmembrane 
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Figure 4: TIMP2 Mediated Activation of proMMP-2 by MT1-MMP 
 
1) TIMP2 binds and inactivates MT1-MMP, 2) Soluble proMMP-2 binds TIMP2 through its 
hemopexin-like domain, 3) A neighboring active MT1-MMP molecule can now associate 
with the MMP/TIMP2  complex, 4) The active MT1-MMP interacts with the complexed MT1-
MMP  and initiates cleavage/activation of proMMP-2, 5a) Active MMP-2 disassociates from 
complex or 5b) Active MMP-2 remains complexed and activates proMMP-9. 
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1.5 Previous Studies 
 
 
Earlier studies from our laboratory and others showed overexpression of LIMK1 in 
various types of cancerous tissues including cancerous prostate tissue. Differential 
expression of LIMK1 also was noted in a variety of prostate cancer (PCa) cell lines and 
normal prostate epithelial cells (PrEC).  Our studies showed elevated LIMK1 expression in all 
cancer cell lines analyzed compared to PrEC (Figure 5). The highest expression of LIMK1 was 
noted in the metastatic prostate cancer line PC-3 and a low to moderate level in the Benign 
Prostatic Hyperplasia cell line BPH-1. A higher level phosphorylated cofilin, a bona fide LIMK1 
substrate was also noted in PC-3 cells compared to BPH-1 cells . To study the function of 
LIMK1 BPH-1 cell line was used for ectopic expression of LIMK1. Several constructs were 
prepared to express full- length as well as mutant LIMK1. These include:  Full length LIMK1; 
Kinase-dead LIMK1; or Constitutively-Active LIMK1. Kinase-dead LIMK1 was generated by 
mutating Asp460   into an alanine, and Constitutively-Active LIMK1 was generated by 
mutating Thr508 into two glutamic acid residues. Our studies further showed that the stable 
expression of full length LIMK1 was enough to induce an invasive phenotype in BPH-1 cells 
and the partial inhibition of LIMK1 in PC-3 cells using anti-sense RNA reduced the number of 
invasive cells [Davila et al. 2003].  Because matrix metalloproteinases (MMPs) are the key 
mediators involved in invasion, a possible correlation between LIMK1 expression and MMPs 
was studied next.  BPH-1 cells expressing constitutively active LIMK1 (BPHLCA) or the control 
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vector (BPHV) were used to study the effect of LIMK1 expression on invasion.  These assays 
were conducted with or without treatment with a broad-spectrum MMP inhibitor, ilomastat 
(GM6001).  The results showed that BPHLCA cells had a 4-5-fold increase in the number 
of invasive cells, and that this invasion was largely blocked by treatment with the MMP 
inhibitor.  This data lead us to speculate that a possible relationship exists between LIMK1 
expression and MMPs. 
To further elucidate this link we monitored the effect of LIMK1 expression on the 
secretion of proMMP-2 and proMMP-9. Elevated expression of MMP-2 and MMP-2 has been 
correlated with increased malignancy. Secretion of these MMPs was studied next using 
Zymography  which  showed  increased  gelatinolytic  activity  of  both  MMP-2  and  MMP-9  
in BPHLCA  cells compared to vector expressing cells.  We also noted increased 
concentrations of proMMP-2 and active MMP-2 in BPHLCA cells, while MMP-9 only 
showed an increase in its latent form. To verify that the increased expression of LIMK1 was 
responsible for these results, we monitored MMP-2 and MMP-9 mRNA levels in BPHLCA 
compared to vector expressing cells by RT-PCR.   We observed a 10 fold increase in MMP-2 
mRNA in BPHLCA compared to vector expressing cells, although the levels of MMP-9 mRNA 
remained relatively unaffected by LIMK1 expression.   This data suggested a possible 
correlation between LIMK1 expression and MT1- MMP,  because  MT1-MMP  is  both  an  
activator  of  MMP-2  and  a  target  of  the  inhibitor,ilomastat. 
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Figure 5: LIMK1 is differentially expressed in human prostate cell lines and prostate tissues 
 
a)  Immunoblot analysis of LIMK1 in total lysates of human prostate cell lines.  b) Expression of 
 
LIMK1 in prostate tissues. Upper panel, Normal/benign areas. Lower panel, cancerous 
glands. Upper and lower left, Hematoxylin/eosin-stained slides. Upper and lower right, areas 
from normal and cancerous tissues are shown in higher magnification (×200). Arrows 
indicate light staining in basal cells in normal/benign areas (upper panel) and intense 
staining in cells in cancerous areas (lower panel) 
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 1.6 Hypothesis/Objectives 
 
 
Based on published studies and preliminary experiments conducted in our laboratory, we 
hypothesize that LIMK1 is involved in the regulation MT1-MMP. To test our hypothesis we 
planned to study 
 
1.  The expression of MT1-MMP in cells differentially expressing LIMK1 
 
 
 
2.  A possible physical association of LIMK1 with MT1-MMP 
 
 
 
3.  Subcellular localization of LIMK1 and MT1-MMP 
 
 
 
4.  Effect of LIMK1 expression on MT1-MMP transport and localization 
 
 
 
5.  Effect of LIMK1 expression on MT1-MMP transcription 
18 
 
 
 
2. MATERIAL AND METHODS: 
 
 
 
 2.1 Cell  Culture and Cell  Lines 
The parental BPH-1 cells (a gift for P Narayana, University of Florida) (Hayward et al., 1995) 
and its transfected sub-lines, were maintained in Dulbecco’s modified Eagle’s medium 
(Sigma-Aldrich) with 10% fetal bovine serum and 1% antibiotic/antimycotic (Invitrogen).  
BPH-1 cells stably overexpressing constitutively active (phosphomimic) LIMK1 with a C-
terminal Flag tag (BPHLCA) and the empty vector control (BPHV) were produced previously 
in the lab.   The LIMK1 phosphomimic (T508EE) was produced by site directed mutagenesis.  
Stable cells were selected using hygromycin and stable populations were mixed to 
prevent clonal bias and continually maintained in media containing hygromycin. PC3 cells 
(ATCC) were maintained in F-12 HAM (Sigma-Aldrich) supplemented with 10% fetal bovine 
serum, 2mM glutamine, and 1% antibiotic/antimycotic. All cells were in a humidified 
atmosphere containing 5% CO2, at 37°C. 
 
 2.2  Immunoblot,  Immunoprecipitation, and Antibodies  
 
For immunoblots, cells were lysed using RIPA lysis buffer (50mM Tris pH 8.0, 
20mM NaCl, 2.5mM EDTA, 1mM PMSF, 1% NP-40, 10ug/mL leupeptin, 10ug/mL aprotinin) 
and freeze thaw cycles.  50ug of whole cell extract was separated by SDS-PAGE and subjected 
19 
 
to western blotting with the appropriate primary and horseradish peroxidase conjugated 
secondary antibodies.   A chemiluminescence kit (Thermo Scientific) was used to detect 
target proteins. For immunoprecipitation, cells were lysed as describe above in RIPA lysis 
buffer containing a proteinase inhibitor mixture set III (Calbiochem EMD).    LIMK1 or MT1-
MMP was immunoprecipitated from 500ug whole cell lysate using 2ug of the appropriate 
primary antibody for 4 hours at 4°C.  Antigen-antibody complexes were 
immunoprecipitated with 40ul protein A/G PLUS Sepharose beads (Santa cruz) for 16-18 
hours at 4°C.  Precipitated proteins were detected by immunoblot analysis and described 
above.
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Table 1: Dilutions of antibodies and incubation times 
 
 
Antibody Company Dilution Incubation 
Time/Temperature 
Flag 
 
LIMK1 
GAPDH 
MT1-MMP 
Sigma 
 
BD biosciences 
 
Sigma 
 
Neomarker 
1:2000 
 
1:100 
 
1:1000 
 
7ug/ml 
1hr/RT 
 
16hr/4°C 
 
1hr/RT 
 
16hr/4°C 
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 2.3 Gene Silencing Using Short Hairpin RNA 
 
LIMK1 expression in PC3 cells was reduced by transfection of HuSH shRNA construct 
against LIMK1 (#3: AAGGACAAGA GGCTCAACTTCATCACTGA) in the pGFP-V-RS vector 
(Origene Technologies).   Four different shRNA constructs targeting LIMK1 were screened 
and the construct with the highest reduction in LIMK1 was used in subsequent 
experiments.   A non- targeting shRNA construct (scr) was created to control for off target 
effects.   PC3 cells were transiently transfected with either construct using Lipofectamine 
or FuGENE HD for 55-72 hours. 
 2.4 Dual and Triple Label Immunofluorescence Analysis 
 
Cells were seeded on poly-L-lysine coated coverslips in 24 well dishes and allowed 
to attach for 24 hours.  For knockdown experiments, PC3 cells were transfected with LIMK1 
shRNA or scrambled shRNA 24 hours after seeding and were maintained for an additional 
24 hours. For immunostaining, cells were washed with phosphate buffer (0.1M) and fixed in 
4% paraformaldehyde at room temperature for 10 minutes.  Cells were then washed with 
either 0.2% Triton X-100 (BPH) or 0.1% Triton X-100 for 3 min or 0.1% Tween-20 for 4 min 
(PC3) in phosphate buffer.   Cells were blocked in phosphate buffer containing 10% goat 
serum, 0.2% Triton X-100 for 1.5 hours at room temperature.  Cells were stained with 
primary antibodies diluted in blocking solution for 1 hour at room temperature.  Cells were 
then washed with blocking solution.  Next, cells were stained with fluorophore-conjugated 
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secondary antibodies diluted in blocking solution for 30 minutes at room temperature.  
Coverslips were then washed in phosphate buffer containing Triton X-100 or Tween-20 as 
described above then post-fixed with 4% paraformaldehyde for 5 minutes at room 
temperature.  Coverslips were mounted with gel mount (BioMeda) and visualized on a Zeiss 
710 confocal microscope.  Colocalization values were quantified by selecting specific regions 
of singly labeled cells to set the thresholds.  The specific regions of interest (vesicles, entire 
cell, or entire membrane) were used for pixel quantification.  Colocalization was quantified 
using Zeiss Zen 2009 software or Olympus FV1- ASW software, which calculates overlap and 
colocalization coefficient as derived from Mander’s article based on Pearson’s correlation 
coefficient. 
 
 
 
The values for the overlap coefficient range from 0 to 1. An Overlap Coefficient with a value of 
1 represents perfectly colocalized pixels. 
 
 
 
 
Because each pixel is subtracted by the average pixel intensity, the value for Correlation R 
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can range from -1 to 1. A value of 1 would mean that the patterns are perfectly similar 
(colocalized), while a value of -1 would mean that the patterns are perfectly opposite. 
24 
 
 
 
 
 
Table 2: Dilutions of antibodies and incubation times 
 
 
 
Primary Antibody Company Dilution Incubation 
Time/Temperature 
Flag 
 
LIMK1 
 
MT1-MMP 
TGN46 
Sigma 
 
BD biosciences 
 
Neomarker 
 
Novus Biologicals 
35mg/mL 
 
1:50 
 
1:200 
 
1:115 
1hr/RT 
 
1hr/RT 
 
1hr/RT 
 
1hr/RT 
 
 
 
2⁰ 
Ab 
Company Dilution  Incubation 
Time/Temperature 
 
Cy3 Jackson Labs 1:300 30min/RT 
 
Cy5 Jackson Labs 1:300 30min/RT 
 
Alexa 647 Invitrogen 1:300 30min/RT 
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 2.5 Dual Luciferase Reporter Assay 
 
Reporter assays were conducted with firefly luciferase driven by a 7.2 KB promoter 
fragment of MT1-MMP in a modified pGL3 parent vector (kindly provided by Jorma Keski-
Oja, University of Helsinki).  Cells were co-transfected with this construct and a transcription 
control construct containing Renilla luciferase driven by thymidine kinase promoter using 
Lipofectamine LTX according to our published protocol (Tapia et al., 2011).  Stably 
transfected BPHLCA and BPHV cells and PC3 cells transiently transfected with LIMK1 shRNA 
or scrambled shRNA were used.  PC3 cells were harvested 62 hours post-transfection.  
Luciferase expression was determined using a Dual luciferase assay kit (Promega) according 
to manufacturer’s protocol. 
 
 
 
 2.6 Statistical  Analysis 
 
Quantitative results are presented as mean ± SD of the number of independent 
experiments performed. A p value of < 0.05 was considered significant.
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3. RESULTS: 
 
 
 3.1 Expression of MT1-MMP Correlates with the Expression of LIMK1  
 
 
MT1-MMP expression has been shown to be elevated in tumors of increasing grade 
and malignancy, as is the expression of LIMK1.  In order to elucidate a possible connection 
between the expression of LIM Kinase 1 and MT1-MMP, we first monitored the expression of 
MT1-MMP in cells differentially expressing LIMK1. Cell lysates from BPH-1, BPHLCA, and PC-3 
were immunoblotted with anti-LIMK1 and anti-MMP antibodies, and expression patterns 
were compared.  We chose to use an antibody targeting the hinge region of MT1-MMP, 
because it recognized all forms of the protein.  Our immunoblot results showed that with 
increasing concentrations of LIM Kinase 1, cells also expressed increasing levels of MT1-MMP 
(Figure 6). Increasing levels of all forms of MT1-MMP such as, latent, active, and 
autocatalytic forms were detected.  To further confirm these findings, we employed shRNA 
mediated down regulation of LIMK1 expression in PC-3 cells.. LIM Kinase inhibition resulted 
in the reduced expression of all forms of MT1-MMP as noted by western blots. 
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Figure 6: Expression of MT1-MMP correlates with LIMK1 Expression 
 
Immunoblot analysis of LIMK1 and MT1-MMP, in total lysates of BPHV, BPHLCA, and PC-3 
cell lines. a) Cells overexpressing LIMK1 display elevated MT1-MMP expression, b) PC-3 
cells expressing LIMK1-shRNA display reduced MT1-MMP expression. 
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 3.2 LIM Kinase 1 Colocalizes & Physically Associates with MT1-MMP 
 
 
We next investigated whether LIMK1 physically interacts with MT1-MMP using 
immunoprecipitation and immunofluorescence analyses. LIMK 1 was immunoprecipitated 
using PC-3 cell lysates and immunoblotted with MT1-MMP. Detected polypeptide bands 
correlated with both active and latent forms of MT1-MMP. A polypeptide band 
corresponding to LIMK1 was also detected in the immunoblots of the reverse 
immunoprecipitation, which confirmed a physical association of LIMK1 with MT1-MMP in a 
complex (Figure 7).  Additionally we noticed that LIMK1 was associating with both latent and 
active forms of MT1-MMP. 
Next we monitored localization of these proteins within PC-3 and BPHLCA cells 
using dual-label immunofluorescence analysis (Figure 8). Our results indicated that both 
LIMK1 and MT1-MMP were colocalized in the Golgi area as well as at the periphery of the 
cell.  To confirm that these proteins were indeed colocalized, quantitative analysis of 
overlapping pixels and intensities was conducted using both Zeiss Zen and Leica LasAF 
Software (Figure 9).   The colocalization values were generated on the basis that photons 
from both intensities/wavelengths, each wavelength correlating to either LIMK1 or MT1-
MMP, were striking the same photo detector cell. The generated values strongly suggest a 
physical interaction between LIMK1 and MT1-MMP at the Golgi area and at the plasma 
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membrane in both PC-3 and BPHLCA cells.   This strengthened the co-immunoprecipitation 
results showing that LIMK1 was interacting, directly or indirectly, with both latent and active 
MT1-MMP. 
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Figure 7: LIMK1 and MT1-MMP Physically Associate 
 
a) Coimmunoprecipitation (Co-IP) and b) Reverse Co-IP of MT1-MMP and LIMK1 using anti- 
LIMK1 (mouse monoclonal) and anti-MT1-MMP (rabbit polyclonal) antibodies and PC3 cell 
extracts (500 μg) showing pull down of MT1-MMP and LIMK1 in immunoprecipitates. Nsp 
mAb: Nonspecific mouse monoclonal antibodies. Rabbit serum and nonspecific mouse mAb 
were used as the negative controls. 
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Figure 8: LIMK1 Colocalizes with MT1-MMP 
 
Immunofluorescence analysis of LIMKT508EE and MT1-MMP in BPHLCA (a-c) and PC3 (d-f) 
cells. a-c: Co-localization of MT1-MMP (red) and LIMK1 (green)(merged image) in these cells 
was mainly to the perinuclear regions at the ER/Golgi area. Colocalization of MT1-MMP with 
LIMK1 was also at the plasma membranes (yellow arrows).These cells showed intense 
staining and accumulation of LIMK1 in the ruffling membranes (Insert: yellow arrows). 
Scale bar 5 μm. d-f:Colocalization of LIMK1 and MT1-MMP in PC3 cells. 
Immunofluorescence analysis of MT1- MMP and LIMK1 showed strong staining of both 
proteins in the Golgi areas and in transport vesicles (yellow arrows). Scale bar 5 μm. 
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Figure 9: Quantitative Analysis of LIMK1 and MT1-MMP Colocalization 
 
Overlap coefficient of actual pixels in designated areas (red circles) at the Golgi region and 
at the membrane for both BPHLCA and PC3 cells. 
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 3.3  LIMK1 Facilitates MT1-MMP Transport Through the Golgi  to the Plasma Membrane 
 
 
From the previous results we were able to infer that LIMK1 was indeed interacting 
with MT1-MMP, and these interactions were occurring at regions of the cell consistent with 
the location of the Golgi network and plasma membrane. To further confirm that these 
proteins were indeed colocalized at the Golgi vesicles we employed triple labeled 
immunofluorescent analysis using antibodies against TGN46, a Golgi/Trans-Golgi Network 
marker.  PC-3 cells were labeled with LIMK1, MT1-MMP, and TGN46 antibodies and the 
colocalization of LIMK1 with MT1-MMP along with the colocalization of TGN46 with 
LIMK1/MT1-MMP was analyzed.  The staining patterns of these proteins indicated transport 
of all three proteins from the Golgi through the Trans-Golgi vesicles to the membrane (Figure 
10). Colocalization of these proteins was analyzed using the Leica LasAF software, which 
generated Pearson’s Correlation values for our selected areas of interest. Pearson’s 
Correlation values range from -1 to +1, meaning that 0% of either molecule is associating 
with the other to 100% association respectively.  The Pearson’s Correlation values analyzing 
the association of LIMK1 or MT1-MMP with TGN46 at the   Golgi/Membrane   were   as   
follows:   LIMK1-TGN46   +0.76/+0.71;   MT1-MMP-TGN46 +0.63/+0.68. Additionally analysis 
of LIMK1 association with MT1-MMP at the Golgi/Membrane generated average Pearson’s 
Correlation values of +0.75/+0.80. This data strongly suggests that LIMK1 is associating with 
34 
 
MT1-MMP at the Golgi and membrane. 
To investigate the effect of inhibition of LIMK1 expression on the transport of MT1- 
MMP, PC-3 cells were transfected with either a plasmid expressing LIMK1-shRNA or non- 
targeting shRNA. After 48 hrs cells were fixed and stained for immunofluorescent 
microscopy. The reduction in LIMK1 and MT1-MMP expressions was confirmed by measuring 
staining intensities by immunofluorescent-microscopy and by western blotting of the 
lysates of PC-3 cells transfected at the same time. Slides were prepared and images were 
taken using the exact experimental conditions (antibody concentrations, laser power, gain, 
filter settings, etc) between LIMK1 knock-down and control slides. PC-3 cells expressing 
LIMK1-shRNA displayed an overall decrease in LIM Kinase 1 and MT1-MMP staining intensity 
compared to cells expressing the control shRNA (Figure 11). We also noticed that cells 
expressing the LIMK1-shRNA have MT1-MMP staining intensity restricted to the 
perinuclear region compared to control shRNA expressing cells. 
To verify that reduction in LIMK1 expression correlates with an inhibition of MT1-
MMP transport to the membrane, we next monitored MT1-MMP intensity at the membrane 
and at Golgi vesicles stained with TGN46. Our data showed an overall reduction in cellular 
MT1-MMP staining intensity following knockdown of LIMK1 (Figure 12). Specific 
quantification of MT1- MMP intensities at Golgi vesicles and at the membrane was then 
conducted (Figure 13). PC-3 cells expressing LIMK1-shRNA displayed an average reduction 
of 1.8-fold in the intensity of MT1-MMP staining at Golgi vesicle compared to control 
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shRNA-expressing cells.  Moreover, the average reduction in MT1-MMP staining was 
further decreased at the membrane (3.1 fold). Additionally there was no significant change 
in the staining intensity or pattern of TGN46 following LIMK1 knockdown and no significant 
change in the colocalization of MT1-MMP with TGN46 at the Golgi or membrane. This 
suggests that LIMK1 expression is promoting MT1-MMP transport to the membrane. 
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   Figure 10: Colocalization of LIMK1 and MT1-MMP at Golgi Vesicles 
Immunolocalization of MT1-MMP and LIMK1 showed strong staining of both proteins in 
the Golgi areas (White staining and long white arrows) along with Golgi marker: TGN46. 
Yellow arrows: Colocalization of MT1-MMP and LIMK1 in Golgi vesicles at various 
distances towards plasma membrane. White arrows: Colocalization of MT1-MMP and 
LIMK1 to the plasma membrane. 
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Reduced Expression of MT1-MMP Following LIMK1 Knockdown in PC-3 Cells 
 
Immunofluorescence and quantitative analysis of the reduction of LIMK1 and MT1-MMP 
expression in LIMK1 shRNA but not scrambled RNA expression vector transfected cells. 
Immunoblot of transfected PC-3 cell lysate confirms loss in expression of MT1-MMP 
following LIMK1 knockdown compared to cells expressing scr shRNA. 
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Figure 12: LIMK1 Knockdown in PC-3 Cells Reduces MT1-MMP Expression and Localization 
to the Plasma Membrane 
 
Immunofluorescence analysis of MT1-MMP, and TGN46 expression and localization in PC3 
cells transfected with scrambled RNA (upper panel) or LIMK1 shRNA (lower panel) expressing 
vectors. Upper panel: Yellow arrows: Colocalization of MT1-MMP with TGN46 in Golgi 
vesicles moving towards the plasma membrane, White arrow: Targeting of MT1-MMP to the 
plasma membrane. Lower panel: Colocalization of MT1-MMP and TGN46 to the perinuclear 
region (yellow arrow) but not in the transport vesicles (orange arrow). White arrow: 
Transport of TGN46 positive Golgi vesicles to the plasma membrane. No targeting of MT1-
MMP could be noted in these cells. A significant reduction in the MT1-MMP concentration 
was also evident in these cells. Scale: 10 μm. 
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Figure 13: Quantification of MT1-MMP Staining Intensities and MT1-MMP/TGN46 
Colocalization at Areas of the Membrane and Golgi 
 
Quantitative analysis of the staining intensity of MT1-MMP in the Golgi vesicles (red circles 
in DIC merge: yellow arrow) and in the membrane (entire membrane) in scrambled RNA 
and LIMK1 shRNA transfected PC3 cells. Pearson’s correlation coefficient analysis confirms 
colocalization between MT1-MMP and TGN46 in Golgi vesicles at the same region used for the 
analysis of staining intensity. 
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 3.4 LIMK1 Expression Promotes Surface Expression of MT1-MMP  
Our immunofluorescent microscopy data showed a correlation between LIMK1 
expression and MT1-MMP localization to the membrane. Surface labeling of MT1-MMP 
was next employed to verify if indeed surface localization of MT1-MMP is regulated by 
LIMK1. Surface MT1-MMP expression was first monitored in BPHLCA cells expressing 
constitutively active LIMK1, or in control BPHV cells. Non-permeabilized cells were labeled 
with antibodies against MT1-MMP, to stain only active MT1-MMP on the plasma membrane. 
FITC-conjugated secondary antibodies were used monitor labeled cells by Flow Cytometry.    
BPHLCA   cells displayed an increased number of MT1-MMP positive stained cells along with 
an increase in average fluorescence compared to BPHV cells.  This can be visualized by the 
increase in peak height and the shift towards the right, respectively, in stained BPHLCA cells 
compared to stained BPHV cells (Figure 14). 
 
We next examined the effect of LIMK1 knock down on MT1-MMP surface expression 
in PC-3 cells by biotin labeling.  PC-3 cells expressing either LIMK1-shRNA or control shRNA, 
with intact membranes, were incubated with Sulfo-NHS-Biotin, a membrane impermeable 
biotin ester. In the presence of primary amine groups, the biotin molecule is transferred to 
the amine group, which results in the biotinylation of all surface proteins.  The cells were 
then lysed, and biotinylated proteins were enriched through immunoprecipitation with 
strepavidin beads.  The immunoprecipitates were resolved by SDS-PAGE and transferred to 
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a PVDF membrane to be blotted with the anti-MT1-MMP antibodies.   Our results showed 
that PC-3 cells transfected with LIMK1-shRNA had reduced levels of biotin labeled MT1-
MMP.   These results show that LIMK1 expression positively correlates with the surface 
expression of MT1-MMP (Figure 15). 
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Figure 14: LIMK1 Expression Positively Regulates Surface Localization of MT1-MMP in BPH 
Cells 
 A) Flow cytometric analysis of MT1-MMP cell surface expression in transfected BPH cell lines. Two-parameter histogram of the surface staining of MT1-MMP with fluorescence intensities in the X-axis and number of cells in the Y-axis in BPH cells expressing LIMK1. Black histogram represents unstained cells. Red histogram represents population of fluorescent cells within each sample. B) Quantitative analysis of fluorescent cells. For densitometric analysis, the BPHLCA cells that were emitting fluorescence were gated out from the nonfluorescent cells and calculated as the percentage of the fluorescent control (BPHV) cells. Data represents the mean ± SD of three independent experiments. *P =0.0005. 
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Figure 15: Inhibition of LIMK1 Expression Reduces Surface Localization of MT1- MMP in PC-
3 Cells 
 
A) Surface biotinylation of MT1-MMP following knock down of LIMK1 in PC3 cells. 
Immunoblot of biotinylated MT1-MMP in the streptavidin bead bound MT1-MMP. Lane 1 
non-biotinylated cells, Lane 2: control shRNA expressing cells, Lane 3: LIMK1 shRNA 
expressing cells. B) Immunoblot analysis of LIMK1 in PC3 cells expressing control shRNA or 
LIMK1 shRNA used for surface biotinylation assays. Data show representative images of 
three independent experiments. 
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 3.5 Expression of LIMK1 is Associated with Increased Transcriptional Activation of MT1-MMP  
 
The expression of matrix-metalloproteinases including MT1-MMP is up-regulated in 
advanced prostate cancer tissues and invasive PCa cell lines.  MT1-MMP expression has 
been correlated with the aggressiveness of prostate cancer cell types and shown to be 
overexpressed in the invasive PCa cell line PC-3.  In PC-3 cells, MT1-MMP transcription is 
regulated through AKT/JNK signaling, leading to activation of the transcription factor Sp1. 
Additionally, treatment with bone morphogenic protein 2 was shown to activate PI3K/AKT 
signaling leading to PAK1/4 phosphorylation and activation of LIMK1.   These reports suggest 
a possible link between LIMK1 activity and MT1-MMP transcription.  To elucidate any 
connection with LIMK1 activity, we used prostate cells differentially expressing LIMK1 and 
monitored MT1-MMP promoter activity using a dual luciferase reporter assay. The Firefly 
luciferase reporter vector was constructed with the full 7.2kb MT1-MMP promoter 
positioned to drive the expression of Firefly luciferase. The MT1- MMP reporter vector was 
co-transfected with a plasmid constitutively expressing Renilla luciferase into BPHLCA and 
BPHV cells along with PC-3 cells expressing LIMK1-shRNA, control shRNA, or only expressing 
the luciferase reporter vectors.   Firefly luciferase activity was measured by the light emitted 
and these values were normalized to Renilla luciferase activity to compensate for 
inconsistencies in transfection and transcription efficiencies (Figure 16). BPHLCA displayed a 
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3-4 fold increase in relative Firefly luciferase activity compared to BPHV cells. This suggests 
that LIMK1 activity positively correlates with MT1-MMP transcriptional activation. 
Furthermore, the knockdown of LIMK1 resulted in significant (95%) and consistent reduction 
in luciferase activity compared to PC-3 cells expressing only the luciferase reporter vectors.  
PC-3 cells expressing the control shRNA displayed some off target effects but LIMK1-shRNA 
cells still displayed reduced luciferase activity.   Although, the luciferase activity of cells 
expressing the control shRNA was similar to the other LIMK1-shRNA vectors tested, which 
were not effective in reducing LIMK1 expression.  This shows that the results generated 
using the LIMK1-shRNA in all of the experiments is not a consequence of off target effects.  
These observations indicate that MT1-MMP transcription is increased with increased 
expression of LIM Kinase 1. 
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Figure 16: Effect of LIMK1 on transcription activation of MT1-MMP 
 
A) Relative luciferase activity in BPHLCA and BPHV cells transfected with MT1-MMP 
promoter luciferase constructs. B) Relative luciferase activity in PC3 cells transfected with 
MT1-MMP promoter luciferase construct alone or in combination with scrambled shRNA or 
LIMK1 shRNA expressing plasmids. Results show Mean ± SD of at least three separate 
experiments. *P =0.0075 (BPHLCA vs. BPHV), **P = 0.004 (PC3 scr shRNA vs. PC3LIMK1 
shRNA),***P = 0.0005 (PC3 vs. PC3LIMK1 shRNA).
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4. DISCUSSION 
 
 
 
The organization and modulation of actin filaments are key processes in cell motility 
and change in cell morphology. Formation of the membrane structures, lamellipodia, 
filopodia, and invadopodia, require the temporal and spatial regulation of proteins involved in 
actin cytoskeleton stability and organization.   Abnormal regulation cytoskeletal dynamics 
would predispose cells to adopting characteristics associated with invasive and metastatic 
cancers. The Rho family of GTPases participates in signaling pathways affecting actin 
organization and was shown to have increased activity in advanced cancers. A downstream 
effector of this pathway is LIMK1, which is activated by Rho/ROCK signaling.   Expression of 
LIMK1 has been linked with advanced metastatic cancers and shown to promote invasion 
in cancer cell lines. Additionally, activity of Rho family members, RhoA and Rac1, promotes 
expression and activation of MMPs involved in invasion and metastasis.  Enhanced 
expression of MT1-MMP is correlated with tumor progression and malignancy. 
 Our studies presented here reveal a role for LIMK1 in the complex regulatory 
scheme of MT1-MMP. The functions of MT1-MMP in metastatic events are well described. 
Therefore, it is very plausible that the ability of LIMK1 to promote cell migration and invasion 
is facilitated by activation of MMPs. Our preliminary results confirmed the participation of 
MT1-MMP, MMP-2, and MMP-9 in the LIM Kinase 1 induced invasion of the benign 
prostatic hyperplasia cell line, (BPHLCA).   The broad inhibitor of MMP activity, 
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ilomastat/GM6001, significantly reduced the number of invasive cells induced by LIMK1 
expression.    This study is the first to report the novel functional association between 
LIMK1 and MT1-MMP. 
To further investigate the link between LIMK1 and MMP, we first asked if LIMK1 
expression was increasing the enzymatic activity of MMPs. Our results showing increased 
processing of MMP-2 in BPHLCA cells addresses this question.  Furthermore, these cells had 
elevated secretion of both proMMP-2 and proMMP-9, a common phenomenon noted in 
prostate cancer patients.   We next explored the possibility that LIMK1 expression was 
modulating the transcription of these MMPs.   Our findings showed a significantly higher 
transcription of MMP-2 in LIMK1 expressing cells. These results lead us to investigate a 
possible connection between LIMK1 and a known activator of MMP-2, MT1-MMP. 
From our immunoblot results we noted an enhanced expression of MT1-MMP in 
prostate cell lines over-expressing LIMK1. This effect was reversed when LIMK1 expression 
was reduced by LIMK1-shRNA in PC-3 cells.   Upon further investigation into this 
relationship, we identified, through co-immunoprecipitation that LIMK1 was physically 
associating with active and latent forms of MT1-MMP. This suggests a possible association 
before and after processing of MT1-MMP in the Golgi. We next monitored the locations of 
these interactions with immunofluorescent microscopy. These results showed colocalization, 
verified by strong Pearson’s correlation values, occurring in the Golgi, Trans-Golgi vesicles, 
and at the cell cortex. Furthermore, colocalization at Golgi vesicles at varying distances 
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from the perinuclear area to the cell membrane suggests a role of LIMK1 in regulating 
vesicular trafficking of MT1-MMP.  To confirm this speculation, we inhibited LIMK1 
expression in PC-3 cells and noted an overall reduction of MT1-MMP expression although 
this reduction was greater at the membrane than at the Golgi.  Taken together, with 
previous reports on the role of LIMK1 in modulating Golgi vesicles and endocytic vesicles, 
strengthens the argument for the involvement of LIMK1 in regulating membrane expression 
of MT1-MMP (Rosso et al., 2004)(Nishimura et al., 2006). Confirmation that LIMK1 was 
indeed involved in the surface expression of MT1-MMP came from our surface labeling 
experiments.   Using flow cytometry we monitored the effect of enhanced expression of 
LIMK1 in BPH-1 cells, which revealed an increase in surface labeled MT1-MMP.  
Conversely, the effect of reduced LIMK1 expression in PC-3 cells was monitored by 
immunoprecipitation of biotinylated surface proteins, which were then immunoblotted 
for MT1-MMP expression.  These immunoblots show reduced MT1-MMP concentrations in 
the immunoprecipitates of cells expressing LIMK1 shRNA. 
Finally our study showed that LIMK1 expression was involved in regulating the 
transcriptional activity of MT1-MMP. We employed the full length MT1-MMP promoter, 
containing a known Sp1 binding site, to drive transcription of Firefly Luciferase.  We were 
than able to quantify the effect of LIMK1 expression on MT1-MMP transcription by 
monitoring the relative activity of Firefly luciferase.  Although the effect of LIMK1 on MT1-
MMP transcription was clearly observable, the underlying mechanism remains to be 
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elucidated.  However the importance of this study lies in the possibility that, through 
regulation of MMPs, LIMK1 may be a more effective therapeutic target without the toxicity 
of inhibitors of MMP activity.
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